Rosetta Genomics said this week that the US Patent and Trademark Office has issued US Patent No. 7,943,745, covering the composition of matter for human hsa-miR-497 and its variants.

The patent is not yet listed in the USPTO database.

Rosetta said that human hsa-miR-497 is an "important component" of its miRview Mets and miRview Mets2 diagnostic tests, used to identify the tissue of origin in cancers of unknown primary.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.